Popular blood thinner associated with higher risk of bleeding complications

When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.

In a study of the three most commonly prescribed blood thinners, the oral anticoagulant rivaroxaban, known by the brand name Xarelto, was associated with a significantly higher risk of bleeding complications than apixaban (brand name Eliquis) and warfarin for patients with blood clots or atrial fibrillation.

The findings, reported at the 2023 American Society of Hematology’s Annual Meeting & Exposition, covered over 10 years of patient data from the Michigan Anticoagulation Quality Improvement Initiative registry. The multi-center initiative is sponsored by Blue Cross Blue Shield of Michigan.

“We found the highest rates of bleeding among patients who took rivaroxaban, followed by warfarin and then apixaban,” said Jordan K. Schaefer, M.D., first author and clinical associate professor of hematology at University of Michigan Medical School.

“We followed patients for over two years on average and were able to compare apixaban to rivaroxaban, something that has not yet been done in a randomized clinical trial. While the findings should be confirmed with randomized studies, they may have implications for providers as they select anticoagulants for their patients.”

Through their analysis, researchers found that if 100 patients were followed over 1 year, rivaroxaban resulted in nearly 40 bleeding events compared to around 25 for warfarin. Bleeding events were similar between apixaban and warfarin, but the latter medication was associated with more major bleeds.

The rate of blood clots was higher with apixaban compared to warfarin, but researchers say it seemed largely driven by other thrombotic events, which included events like heart attacks.

Of the three medications, apixaban was associated with a lower mortality rate than rivaroxaban and warfarin.

“These three medications are the most commonly prescribed anticoagulants for thrombosis and atrial fibrillation, and it is important that we continue to investigate the possible effect they carry as we attempt to best serve our patients,” said Geoffrey Barnes, M.D., M.Sc., senior author and associate professor of cardiology-internal medicine at U-M Medical School.

Additional authors include Josh Errickson, Ph.D., Xiaowen Kong, Naina Chipalkatti, M.D., Brian Haymart, R.N., Suman L. Wood, M.D., MSCE, and James Froehlich, M.D., M.P.H., all of University of Michigan, Mona A. Ali, PharmD., Corewell Health William Beaumont University Hospital, Scott Kaatz, D.O., M.Sc., Gregory D. Krol, M.D., both of Henry Ford Health.

Schaefer reports a consulting relationship with Pfizer. Barnes reports a consulting relationship with Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular and Boston Scientific.

The opinions, beliefs and viewpoints expressed by the authors do not necessarily reflect those of Blue Cross Blue Shield of any of its employees.